Israel’s Taro Sues India’s Sun Over Sale Plans For Irish Unit
This article was originally published in PharmAsia News
The canceled sale of India's Sun Pharma to Israel's Taro Pharma has led to a lawsuit filed in Israel over Sun efforts to stop the associated sale of Taro holdings in Ireland. Last month, Taro withdrew plans to acquire Sun for $460 million. The planned merger had involved Taro selling its Irish operations, but required Sun's consent, which Taro says Sun now refuses to give. Taro also has pending another suit against Sun involving alleged Sun efforts to increase its voting power in Taro. (Click here for more
You may also be interested in...
NEW DELHI - Citigroup Global Markets reiterated its buy on Sun Pharma, India's largest drug company by market capitalization, saying a recent price dip related to a disputed merger attempt with Israel's Taro Pharma offers a "window of opportunity.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.